Argatroban is used as an anticoagulant, primarily in patients who develop heparin-induced thrombocytopenia (HIT), a serious complication from heparin therapy. It directly inhibits thrombin, both free and clot-bound, preventing the formation of fibrin clots. Because it does not require platelet activation, it is safe for use in HIT where immune-mediated platelet activation is a concern. Argatroban is commonly administered during percutaneous coronary interventions (PCI) in HIT patients and is also used in continuous renal replacement therapy (CRRT) for anticoagulation in critically ill patients. Its short half-life allows for rapid adjustment of anticoagulation levels, making it suitable for use in unstable clinical settings. Monitoring is done via activated partial thromboplastin time (aPTT), and dose adjustments are often needed in liver impairment due to hepatic metabolism.